PRIMA-1, a small molecule, has been reported to restore mutant p53 activity via binding to DNA and induction of apoptosis in p53-deleted AML, which enhances the sensitivity of chemotherapy drugs (50). The gene discussed is TP53; the disease is acute myeloid leukemia.